NCT04913103View on ClinicalTrials.gov

Study of PV in Combination With Bendamustine and Rituximab for Patients With R/R MCL

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2027

Conditions
Lymphoma, Mantle-Cell
Interventions
DRUG

Polatuzumab vedotin

treatment by a study drug polatuzumab-vedotin, i.v.

DRUG

Bendamustine Hydrochloride

treatment by a study drug bendamustin i.v.

DRUG

Rituximab

treatment by a study drug rituximab, i.v.

Trial Locations (7)

12800

Charles University General Hospital, Prague

70852

University Hospital Ostrava, Ostrava

625 00

University Hospital Brno, Brno

500 05

University Hospital Hradec Králové, Hradec Králové

775 20

University Hospital Olomouc, Olomouc

323 00

University Hospital Plzeň, Pilsen

100 00

University Hospital Kralovske Vinohrady, Prague

All Listed Sponsors
lead

Czech Lymphoma Study Group

OTHER